Condition: Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer · Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer.
This description comes directly from the study's public registry record.
xiao zhang · 17631117415 · kobe.zhang@innoventbio.com
Always discuss trial participation with your own doctor first.
| Liaoning Cancer Hospital and Institute | Shenyang, Liaoning, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07122687